Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD). Current lipid-modifying therapies, including statins, ezetimibe, bempedoic acid, fibrates, omega-3 fatty acid compounds, and PCSK9 inhibitors, focus on improving lipid levels with the end goal of reducing the risk of CVD. Statins dominate the market owing to their good risk-benefit profiles and evidence of their ability to reduce CV morbidity and mortality. The positive CV outcomes trial (CVOT) data for some nonstatin therapies such as the PCSK9 inhibitors and Vascepa are expected to open the market to these branded agents. The launches of emerging therapies, including Novartis’s inclisiran and Pfizer's vupanorsen, will further expand the array of dyslipidemia drug treatments, although the highly genericized market will see these novel agents used in later lines of therapy.
- What is the impact of the genericization of statins and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) on the dyslipidemia therapy market?
- How are the PCSK9 inhibitors Repatha and Praluent positioned in the dyslipidemia market? How will inclisiran impact the market penetration of Repatha and Praluent after it launches?
- How will the launch of Esperion Therapeutics’ orally administered bempedoic acid and its FDC affect the use of the injectable PCSK9 inhibitors? Which product will experience the most use and why?
- What impact will the launch of Pfizer's vupanorsen and the label expansion and genericization of Vascepa have on the management of hypertriglyceridemia?
DRG’s Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with thought-leading lipidologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Prevalent cases of dyslipidemia by country, CVD prevention setting, and diagnosed/drug-treated populations.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key dyslipidemia therapies through 2029, segmented by brands/generics and CVD prevention setting.
- Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Rohit Bansal, MS (Pharm.); Sandeep Mahapatra, BDS, MPH
Rohit joined Decision Resources Group (DRG)’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team in April 2019. His current focus includes non-alcoholic steatohepatitis (NASH), glomerulonephritis, and renal anemia. Prior to joining DRG, Rohit worked as analyst helping pharmaceutical clients address their business questions across various therapeutic areas.
Rohit’s postgraduate research centered on molecular dynamics. His work included computer-aided drug design software that involved studying the effect of pharmaceutical excipients on the reabsorption of drug molecules from cancer cells leading to drug resistance.
Sandeep is a dental graduate with a Master’s in Public Health with a specialization in Epidemiology and has been associated with DRG since June 2018. He works with a global team of epidemiologists in performing fully documented systematic reviews of published and grey literature on epidemiology of diseases and their risk factors. He also conducts analysis on descriptive epidemiology of major indications in mature and developing markets. Additionally, he supports the operational and strategic management of the team and wider business unit through collation of data from various sources.
Prior to joining DRG he had over 5 years of experience working with state and central government of India to plan, design and conduct large scale research and implementation projects on non-communicable diseases, tobacco cessation and childhood nutrition.